Reunion Neuroscience, a clinical-stage biopharmaceutical company focused on next-generation psychedelic-inspired therapies for mental health, announced the final closing of its Series A financing, raising a total of $133 million. This increase follows positive efficacy results from the RECONNECT study, which met key statistical and clinical milestones.
The additional funding will fully support the ongoing REKINDLE Phase 2 trial studying RE104 for Adjustment Disorder (AjD) in patients with cancer and other medical illnesses, and will enable the expansion of RE104’s clinical development into generalized anxiety disorder (GAD). Reunion plans to initiate the RECLAIM Phase 2 trial in early 2026 to evaluate RE104’s safety and effectiveness in adults with GAD.
GAD is a common mental health condition affecting nearly 7 million adults annually in the U.S., characterized by persistent, excessive anxiety that disrupts daily life. Current treatments, including SSRIs, SNRIs, and cognitive behavioral therapy, often fail to bring remission for many patients, highlighting the urgent need for new therapeutic options.
Greg Mayes, CEO of Reunion Neuroscience, expressed optimism about RE104’s potential, citing its rapid onset and robust clinical benefits demonstrated in postpartum depression (PPD) and adjustment disorder trials. He emphasized the company’s commitment to addressing unmet needs across multiple mental health disorders.
The RECLAIM trial will be a multicenter, randomized, double-blind, dose-controlled study, with the primary endpoint measuring changes in anxiety severity using the Hamilton Anxiety Scale at Week 4.
Reunion’s recent RECONNECT study in PPD showed significant reductions in depression scores and a favorable safety profile, supporting plans to advance RE104 into Phase 3 trials in 2026.
Industry investors, including MPM BioImpact and Novo Holdings, praised Reunion’s progress and the promise of RE104 as a novel treatment option for underserved mental health conditions.